O	O	0	8	Analysis	Analysis	B-NP	NN	O	0	ROOT	O
O	O	9	11	of	of	B-PP	IN	O	1	NMOD	O
O	O	12	15	the	the	B-NP	DT	O	7	NMOD	O
T10	B-Entity	16	22	ligand	ligand	I-NP	NN	B-protein	7	NMOD	B-protein
T10	I-Entity	22	23	-	-	B-PP	HYPH	I-protein	7	NMOD	I-protein
T10	I-Entity	23	30	binding	bind	B-NP	VBG	I-protein	7	NMOD	I-protein
T10	I-Entity	31	37	domain	domain	I-NP	NN	I-protein	2	PMOD	I-protein
O	O	38	40	of	of	B-PP	IN	O	7	NMOD	O
T1	B-Protein	41	46	human	human	B-NP	JJ	B-protein	13	NMOD	B-protein
T1	I-Protein	47	55	retinoic	retinoic	I-NP	JJ	I-protein	13	NMOD	I-protein
T1	I-Protein	56	60	acid	acid	I-NP	NN	I-protein	13	NMOD	I-protein
T1	I-Protein	61	69	receptor	receptor	I-NP	NN	I-protein	13	NMOD	I-protein
T1	I-Protein	70	75	alpha	alpha	I-NP	NN	I-protein	8	PMOD	I-protein
O	O	76	78	by	by	B-PP	IN	O	1	NMOD	O
O	O	79	83	site	site	B-NP	NN	O	18	NMOD	O
O	O	83	84	-	-	O	HYPH	O	18	NMOD	O
O	O	84	92	directed	direct	B-NP	VBN	O	18	NMOD	O
O	O	93	104	mutagenesis	mutagenesis	I-NP	NN	O	14	PMOD	O
O	O	104	105	.	.	O	.	O	1	P	O

O	O	107	112	Three	Three	B-NP	CD	O	2	NMOD	O
O	O	113	121	subtypes	subtype	I-NP	NNS	O	22	SUB	O
O	O	122	124	of	of	B-PP	IN	O	2	NMOD	O
O	O	125	133	retinoic	retinoic	B-NP	JJ	B-protein	6	NMOD	B-protein
O	O	134	138	acid	acid	I-NP	NN	I-protein	6	NMOD	I-protein
O	O	139	148	receptors	receptor	I-NP	NNS	I-protein	3	PMOD	I-protein
O	O	149	150	(	(	O	(	O	9	DEP	O
O	O	150	153	RAR	RAR	B-NP	NN	B-protein	9	DEP	B-protein
O	O	153	154	)	)	O	)	O	6	NMOD	O
O	O	154	155	,	,	O	,	O	2	P	O
O	O	156	162	termed	term	B-NP	VBN	O	2	NMOD	O
T2	B-Protein	163	166	RAR	RAR	I-NP	NN	B-protein	13	NMOD	B-protein
T2	I-Protein	167	172	alpha	alpha	I-NP	NN	I-protein	20	NMOD	I-protein
O	O	172	173	,	,	O	,	O	20	P	O
T3	B-Protein	174	177	RAR	RAR	B-NP	NN	B-protein	16	NMOD	B-protein
T3	I-Protein	178	182	beta	beta	I-NP	NN	I-protein	20	NMOD	I-protein
O	O	182	183	,	,	O	,	O	20	P	O
O	O	184	187	and	and	O	CC	O	20	NMOD	O
T4	B-Protein	188	191	RAR	RAR	B-NP	NN	B-protein	20	NMOD	B-protein
T4	I-Protein	192	197	gamma	gamma	I-NP	NN	I-protein	11	VMOD	I-protein
O	O	197	198	,	,	O	,	O	2	P	O
O	O	199	203	have	have	B-VP	VBP	O	0	ROOT	O
O	O	204	208	been	be	I-VP	VBN	O	22	VC	O
O	O	209	218	described	describe	I-VP	VBN	O	23	VC	O
O	O	218	219	.	.	O	.	O	22	P	O

O	O	220	224	They	They	B-NP	PRP	O	2	SUB	O
O	O	225	228	are	be	B-VP	VBP	O	0	ROOT	O
O	O	229	237	composed	compose	I-VP	VBN	O	2	VC	O
O	O	238	240	of	of	B-PP	IN	O	3	VMOD	O
O	O	241	250	different	different	B-NP	JJ	O	7	NMOD	O
T11	B-Entity	251	261	structural	structural	I-NP	JJ	B-protein	7	NMOD	B-protein
T11	I-Entity	262	269	domains	domain	I-NP	NNS	I-protein	4	PMOD	I-protein
O	O	269	270	,	,	O	,	O	7	P	O
O	O	271	280	including	include	B-PP	VBG	O	7	NMOD	O
O	O	281	289	distinct	distinct	B-NP	JJ	O	11	NMOD	O
O	O	290	297	domains	domain	I-NP	NNS	O	9	PMOD	O
O	O	298	301	for	for	B-PP	IN	O	11	NMOD	O
O	O	302	305	DNA	DNA	B-NP	NN	O	16	NMOD	O
O	O	306	309	and	and	I-NP	CC	O	16	NMOD	O
O	O	310	316	ligand	ligand	I-NP	NN	O	16	NMOD	O
O	O	317	324	binding	binding	I-NP	NN	O	12	PMOD	O
O	O	324	325	.	.	O	.	O	2	P	O

O	O	326	330	RARs	RAR	B-NP	NNS	B-protein	3	SUB	B-protein
O	O	331	343	specifically	specifically	B-ADVP	RB	O	3	VMOD	O
O	O	344	348	bind	bind	B-VP	VBP	O	0	ROOT	O
O	O	349	352	all	all	B-ADVP	RB	O	3	VMOD	O
O	O	352	353	-	-	B-ADJP	HYPH	O	3	P	O
O	O	353	358	trans	trans	I-ADJP	AFX	O	22	NMOD	O
O	O	358	359	-	-	I-ADJP	HYPH	O	22	P	O
O	O	359	367	retinoic	retinoic	B-NP	JJ	O	9	NMOD	O
O	O	368	372	acid	acid	I-NP	NN	O	22	NMOD	O
O	O	373	374	(	(	O	(	O	12	DEP	O
O	O	374	376	RA	RA	B-NP	NN	O	12	DEP	O
O	O	376	377	)	)	O	)	O	9	NMOD	O
O	O	377	378	,	,	O	,	O	22	P	O
O	O	379	380	9	9	B-NP	CD	O	18	NMOD	O
O	O	380	381	-	-	I-NP	HYPH	O	18	NMOD	O
O	O	381	384	cis	cis	I-NP	NN	B-protein	18	NMOD	B-protein
O	O	384	385	-	-	I-NP	HYPH	O	18	NMOD	O
O	O	385	387	RA	RA	I-NP	NN	O	22	NMOD	O
O	O	387	388	,	,	O	,	O	22	P	O
O	O	389	392	and	and	O	CC	O	22	NMOD	O
O	O	393	401	retinoid	retinoid	B-NP	NN	O	22	NMOD	O
O	O	402	409	analogs	analog	I-NP	NNS	O	3	VMOD	O
O	O	409	410	.	.	O	.	O	3	P	O

O	O	411	413	In	In	B-PP	IN	O	6	VMOD	O
O	O	414	418	this	this	B-NP	DT	O	3	NMOD	O
O	O	419	424	study	study	I-NP	NN	O	1	PMOD	O
O	O	424	425	,	,	O	,	O	6	P	O
O	O	426	428	we	we	B-NP	PRP	O	6	SUB	O
O	O	429	437	examined	examine	B-VP	VBD	O	0	ROOT	O
O	O	438	441	the	the	B-NP	DT	O	9	NMOD	O
O	O	442	452	functional	functional	I-NP	JJ	O	9	NMOD	O
O	O	453	457	role	role	I-NP	NN	O	6	OBJ	O
O	O	458	460	of	of	B-PP	IN	O	9	NMOD	O
T12	B-Entity	461	469	cysteine	cysteine	B-NP	NN	O	13	NMOD	O
O	O	470	473	and	and	O	CC	O	13	NMOD	O
T13	B-Entity	474	482	arginine	arginine	B-NP	NN	O	14	NMOD	O
T13	I-Entity	483	491	residues	residue	I-NP	NNS	O	10	PMOD	O
O	O	492	494	in	in	B-PP	IN	O	9	NMOD	O
O	O	495	498	the	the	B-NP	DT	O	20	NMOD	O
T14	B-Entity	499	505	ligand	ligand	I-NP	NN	B-protein	20	NMOD	B-protein
T14	I-Entity	505	506	-	-	B-PP	HYPH	I-protein	20	NMOD	I-protein
T14	I-Entity	506	513	binding	bind	B-NP	VBG	I-protein	20	NMOD	I-protein
T14	I-Entity	514	520	domain	domain	I-NP	NN	I-protein	15	PMOD	I-protein
O	O	521	523	of	of	B-PP	IN	O	20	NMOD	O
T5	B-Protein	524	528	hRAR	hRAR	B-NP	NN	B-protein	23	NMOD	B-protein
T5	I-Protein	529	534	alpha	alpha	I-NP	NN	I-protein	21	PMOD	I-protein
O	O	535	536	(	(	O	(	O	35	DEP	O
T6	B-Protein	536	540	hRAR	hRAR	B-NP	NN	B-protein	35	DEP	B-protein
T6	I-Protein	541	546	alpha	alpha	O	SYM	I-protein	35	P	I-protein
T15	B-Entity	546	547	-	-	O	HYPH	O	35	DEP	O
T15	I-Entity	547	550	LBD	LBD	B-NP	NN	B-protein	31	NMOD	B-protein
O	O	550	551	,	,	O	,	O	31	P	O
T16	B-Entity	552	557	amino	amino	B-NP	NN	B-protein	31	NMOD	B-protein
T16	I-Entity	558	563	acids	acid	I-NP	NNS	I-protein	35	DEP	I-protein
T16	I-Entity	564	567	154	154	B-NP	CD	I-protein	34	NMOD	I-protein
T16	I-Entity	568	570	to	to	B-PP	TO	I-protein	34	NMOD	I-protein
T16	I-Entity	571	574	462	462	B-NP	CD	I-protein	31	NMOD	I-protein
O	O	574	575	)	)	O	)	O	20	NMOD	O
O	O	575	576	.	.	O	.	O	6	P	O

O	O	577	580	All	All	B-NP	DT	O	6	NMOD	O
O	O	581	590	conserved	conserve	I-NP	VBN	O	6	NMOD	O
T17	B-Entity	591	599	cysteine	cysteine	I-NP	NN	O	5	NMOD	O
O	O	600	603	and	and	I-NP	CC	O	5	NMOD	O
T18	B-Entity	604	612	arginine	arginine	I-NP	NN	O	6	NMOD	O
T18	I-Entity	613	621	residues	residue	I-NP	NNS	O	10	SUB	O
O	O	622	624	in	in	B-PP	IN	O	6	NMOD	O
O	O	625	629	this	this	B-NP	DT	O	9	NMOD	O
O	O	630	636	domain	domain	I-NP	NN	O	7	PMOD	O
O	O	637	641	were	be	B-VP	VBD	O	22	VMOD	O
O	O	642	649	mutated	mutate	I-VP	VBN	O	10	VC	O
O	O	650	652	by	by	B-PP	IN	O	11	VMOD	O
T19	B-Entity	653	657	site	site	B-NP	NN	O	16	NMOD	O
O	O	657	658	-	-	O	HYPH	O	16	NMOD	O
O	O	658	666	directed	direct	B-NP	VBN	O	16	NMOD	O
O	O	667	678	mutagenesis	mutagenesis	I-NP	NN	O	12	PMOD	O
O	O	678	679	,	,	O	,	O	22	P	O
O	O	680	683	and	and	O	CC	O	22	VMOD	O
O	O	684	687	the	the	B-NP	DT	O	21	NMOD	O
O	O	688	694	mutant	mutant	I-NP	JJ	B-protein	21	NMOD	B-protein
O	O	695	703	proteins	protein	I-NP	NNS	I-protein	22	SUB	I-protein
O	O	704	708	were	be	B-VP	VBD	O	0	ROOT	O
O	O	709	722	characterized	characterize	I-VP	VBN	O	22	VC	O
O	O	723	725	by	by	B-PP	IN	O	23	VMOD	O
O	O	726	734	blocking	block	B-VP	VBG	O	26	NMOD	O
O	O	735	744	reactions	reaction	B-NP	NNS	O	38	NMOD	O
O	O	744	745	,	,	O	,	O	38	P	O
O	O	746	752	ligand	ligand	B-NP	NN	O	31	NMOD	O
O	O	752	753	-	-	B-VP	HYPH	O	31	NMOD	O
O	O	753	760	binding	bind	B-NP	VBG	O	31	NMOD	O
O	O	761	772	experiments	experiment	I-NP	NNS	O	38	NMOD	O
O	O	772	773	,	,	O	,	O	38	P	O
O	O	774	789	transactivation	transactivation	B-NP	NN	O	34	NMOD	O
O	O	790	796	assays	assay	I-NP	NNS	O	38	NMOD	O
O	O	796	797	,	,	O	,	O	38	P	O
O	O	798	801	and	and	O	CC	O	38	NMOD	O
O	O	802	810	protease	protease	B-NP	NN	B-protein	38	NMOD	B-protein
O	O	811	818	mapping	mapping	I-NP	NN	O	24	PMOD	O
O	O	818	819	.	.	O	.	O	22	P	O

O	O	820	827	Changes	Change	B-NP	NNS	O	12	SUB	O
O	O	828	830	of	of	B-PP	IN	O	1	NMOD	O
O	O	831	834	any	any	B-NP	DT	O	5	NMOD	O
T20	B-Entity	835	843	cysteine	cysteine	I-NP	NN	O	5	NMOD	O
T20	I-Entity	844	851	residue	residue	I-NP	NN	O	2	PMOD	O
O	O	852	854	of	of	B-PP	IN	O	5	NMOD	O
O	O	855	858	the	the	B-NP	DT	O	11	NMOD	O
T7	B-Protein	859	863	hRAR	hRAR	I-NP	NN	B-protein	9	NMOD	B-protein
T7	I-Protein	864	869	alpha	alpha	O	SYM	I-protein	11	NMOD	I-protein
T21	B-Entity	869	870	-	-	O	HYPH	O	11	NMOD	O
T21	I-Entity	870	873	LBD	LBD	B-NP	NN	B-protein	6	PMOD	B-protein
O	O	874	877	had	have	B-VP	VBD	O	0	ROOT	O
O	O	878	880	no	no	B-NP	DT	O	15	NMOD	O
O	O	881	892	significant	significant	I-NP	JJ	O	15	NMOD	O
O	O	893	902	influence	influence	I-NP	NN	O	12	OBJ	O
O	O	903	905	on	on	B-PP	IN	O	12	VMOD	O
O	O	906	909	the	the	B-NP	DT	O	18	NMOD	O
O	O	910	917	binding	binding	I-NP	NN	O	28	NMOD	O
O	O	918	920	of	of	B-PP	IN	O	18	NMOD	O
O	O	921	924	all	all	B-NP	RB	O	23	NMOD	O
O	O	924	925	-	-	I-NP	HYPH	O	23	NMOD	O
O	O	925	930	trans	trans	I-NP	JJ	O	23	NMOD	O
O	O	931	933	RA	RA	I-NP	NN	O	19	PMOD	O
O	O	934	936	or	or	O	CC	O	28	NMOD	O
O	O	937	938	9	9	B-NP	CD	O	28	NMOD	O
O	O	938	939	-	-	I-NP	HYPH	O	28	NMOD	O
O	O	939	942	cis	cis	I-NP	NN	O	28	NMOD	O
O	O	943	945	RA	RA	I-NP	NN	O	16	PMOD	O
O	O	945	946	.	.	O	.	O	12	P	O

O	O	947	960	Interestingly	Interestingly	B-ADVP	RB	O	7	VMOD	O
O	O	960	961	,	,	O	,	O	7	P	O
T22	B-Entity	962	969	residue	residue	B-NP	NN	O	6	NMOD	O
T22	I-Entity	970	971	C	C	I-NP	NN	O	6	NMOD	O
T22	I-Entity	971	972	-	-	O	HYPH	O	6	P	O
T22	I-Entity	972	975	235	235	B-NP	CD	O	7	SUB	O
O	O	976	978	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	979	991	specifically	specifically	B-ADJP	RB	O	7	VMOD	O
O	O	992	1001	important	important	I-ADJP	JJ	O	7	PRD	O
O	O	1002	1004	in	in	B-PP	IN	O	7	VMOD	O
O	O	1005	1015	antagonist	antagonist	B-NP	NN	O	12	NMOD	O
O	O	1016	1023	binding	binding	I-NP	NN	O	10	PMOD	O
O	O	1023	1024	.	.	O	.	O	7	P	O

O	O	1025	1029	With	With	B-PP	IN	O	0	ROOT	O
O	O	1030	1037	respect	respect	B-NP	NN	O	1	PMOD	O
O	O	1038	1040	to	to	B-PP	TO	O	2	NMOD	O
T23	B-Entity	1041	1049	arginine	arginine	B-NP	NN	O	5	NMOD	O
T23	I-Entity	1050	1058	residues	residue	I-NP	NNS	O	3	PMOD	O
O	O	1058	1059	,	,	O	,	O	1	PMOD	O
O	O	1060	1064	only	only	B-NP	RB	O	11	NMOD	O
O	O	1065	1068	the	the	I-NP	DT	O	11	NMOD	O
O	O	1069	1072	two	two	I-NP	CD	O	11	NMOD	O
O	O	1073	1079	single	single	I-NP	JJ	O	11	NMOD	O
O	O	1080	1089	mutations	mutation	I-NP	NNS	O	6	OBJ	O
O	O	1090	1092	of	of	B-PP	IN	O	11	NMOD	O
T24	B-Entity	1093	1094	R	R	B-NP	NN	B-protein	22	SUB	B-protein
T24	I-Entity	1094	1095	-	-	B-NP	HYPH	O	22	VMOD	O
T24	I-Entity	1095	1098	276	276	I-NP	CD	O	22	SUB	O
O	O	1099	1102	and	and	I-NP	CC	O	22	VMOD	O
T25	B-Entity	1103	1104	R	R	I-NP	NN	B-protein	22	SUB	B-protein
T25	I-Entity	1104	1105	-	-	O	SYM	O	17	NMOD	O
T25	I-Entity	1105	1108	394	394	B-NP	CD	O	18	PMOD	O
O	O	1109	1111	to	to	B-PP	TO	O	19	NMOD	O
T26	B-Entity	1112	1119	alanine	alanine	B-NP	NN	O	20	PMOD	O
O	O	1120	1126	showed	show	B-VP	VBD	O	12	SBAR	O
O	O	1127	1128	a	a	B-NP	DT	O	25	NMOD	O
O	O	1129	1137	dramatic	dramatic	I-NP	JJ	O	25	NMOD	O
O	O	1138	1146	decrease	decrease	I-NP	NN	O	22	OBJ	O
O	O	1147	1149	of	of	B-PP	IN	O	25	NMOD	O
O	O	1150	1157	agonist	agonist	B-NP	NN	O	29	NMOD	O
O	O	1158	1161	and	and	I-NP	CC	O	29	NMOD	O
O	O	1162	1172	antagonist	antagonist	I-NP	NN	O	30	NMOD	O
O	O	1173	1180	binding	binding	I-NP	NN	O	26	PMOD	O
O	O	1181	1188	whereas	whereas	B-PP	IN	O	22	VMOD	O
O	O	1189	1192	the	the	B-NP	DT	O	34	NMOD	O
T27	B-Entity	1193	1198	R272A	R272A	I-NP	NN	O	34	NMOD	O
O	O	1199	1207	mutation	mutation	I-NP	NN	O	35	SUB	O
O	O	1208	1214	showed	show	B-VP	VBD	O	31	SBAR	O
O	O	1215	1219	only	only	B-NP	RB	O	39	NMOD	O
O	O	1220	1221	a	a	I-NP	DT	O	39	NMOD	O
O	O	1222	1228	slight	slight	I-NP	JJ	O	39	NMOD	O
O	O	1229	1235	effect	effect	I-NP	NN	O	35	OBJ	O
O	O	1235	1236	.	.	O	.	O	1	P	O

O	O	1237	1240	For	For	B-PP	IN	O	11	VMOD	O
O	O	1241	1244	all	all	B-NP	DT	O	5	NMOD	O
O	O	1245	1250	other	other	I-NP	JJ	O	5	NMOD	O
T28	B-Entity	1251	1259	arginine	arginine	I-NP	NN	O	5	NMOD	O
O	O	1260	1269	mutations	mutation	I-NP	NNS	O	1	PMOD	O
O	O	1269	1270	,	,	O	,	O	11	P	O
O	O	1271	1273	no	no	B-NP	DT	O	8	NMOD	O
O	O	1274	1285	differences	difference	I-NP	NNS	O	11	SUB	O
O	O	1286	1288	in	in	B-PP	IN	O	8	NMOD	O
O	O	1289	1297	affinity	affinity	B-NP	NN	O	9	PMOD	O
O	O	1298	1302	were	be	B-VP	VBD	O	0	ROOT	O
O	O	1303	1313	detectable	detectable	B-ADJP	JJ	O	11	PRD	O
O	O	1313	1314	.	.	O	.	O	11	P	O

O	O	1315	1318	The	The	B-NP	DT	O	3	NMOD	O
O	O	1319	1322	two	two	I-NP	CD	O	3	NMOD	O
O	O	1323	1332	mutations	mutation	I-NP	NNS	O	7	SUB	O
T29	B-Entity	1333	1338	R217A	R217A	I-NP	NN	O	6	NMOD	O
O	O	1339	1342	and	and	I-NP	CC	O	6	NMOD	O
T30	B-Entity	1343	1348	R294A	R294A	I-NP	NN	O	3	NMOD	O
O	O	1349	1355	caused	cause	B-VP	VBD	O	0	ROOT	O
O	O	1356	1358	an	an	B-NP	DT	O	11	NMOD	O
O	O	1359	1368	increased	increase	I-NP	VBN	O	11	NMOD	O
O	O	1369	1376	binding	binding	I-NP	NN	O	11	NMOD	O
O	O	1377	1387	efficiency	efficiency	I-NP	NN	O	16	NMOD	O
O	O	1388	1391	for	for	B-PP	IN	O	11	NMOD	O
O	O	1392	1403	antagonists	antagonist	B-NP	NNS	O	12	PMOD	O
O	O	1404	1407	but	but	O	CC	O	16	NMOD	O
O	O	1408	1410	no	no	B-NP	DT	O	16	NMOD	O
O	O	1411	1417	change	change	I-NP	NN	O	7	OBJ	O
O	O	1418	1420	in	in	B-PP	IN	O	16	NMOD	O
O	O	1421	1428	agonist	agonist	B-NP	NN	O	19	NMOD	O
O	O	1429	1436	binding	binding	I-NP	NN	O	17	PMOD	O
O	O	1436	1437	.	.	O	.	O	7	P	O

O	O	1438	1442	From	From	B-PP	IN	O	6	VMOD	O
O	O	1443	1448	these	these	B-NP	DT	O	3	NMOD	O
O	O	1449	1456	results	result	I-NP	NNS	O	1	PMOD	O
O	O	1456	1457	,	,	O	,	O	6	P	O
O	O	1458	1460	we	we	B-NP	PRP	O	6	SUB	O
O	O	1461	1464	can	can	B-VP	MD	O	0	ROOT	O
O	O	1465	1473	conclude	conclude	I-VP	VB	O	6	VC	O
O	O	1474	1478	that	that	B-SBAR	IN	O	7	VMOD	O
O	O	1479	1492	electrostatic	electrostatic	B-NP	JJ	O	10	NMOD	O
O	O	1493	1505	interactions	interaction	I-NP	NNS	O	19	SUB	O
O	O	1506	1508	of	of	B-PP	IN	O	10	NMOD	O
O	O	1509	1518	retinoids	retinoid	B-NP	NNS	O	11	PMOD	O
O	O	1519	1523	with	with	B-PP	IN	O	10	NMOD	O
O	O	1524	1527	the	the	B-NP	DT	O	18	NMOD	O
T8	B-Protein	1528	1531	RAR	RAR	I-NP	NN	B-protein	16	NMOD	B-protein
T8	I-Protein	1532	1537	alpha	alpha	O	SYM	I-protein	18	NMOD	I-protein
T31	B-Entity	1537	1538	-	-	O	HYPH	O	18	NMOD	O
T31	I-Entity	1538	1541	LBD	LBD	B-NP	NN	B-protein	13	PMOD	B-protein
O	O	1542	1546	play	play	B-VP	VBP	O	8	SBAR	O
O	O	1547	1548	a	a	B-NP	DT	O	22	NMOD	O
O	O	1549	1560	significant	significant	I-NP	JJ	O	22	NMOD	O
O	O	1561	1565	role	role	I-NP	NN	O	19	OBJ	O
O	O	1566	1568	in	in	B-PP	IN	O	19	VMOD	O
O	O	1569	1575	ligand	ligand	B-NP	NN	O	25	NMOD	O
O	O	1576	1583	binding	binding	I-NP	NN	O	23	PMOD	O
O	O	1583	1584	.	.	O	.	O	6	P	O

O	O	1585	1587	In	In	B-PP	IN	O	5	VMOD	O
O	O	1588	1596	addition	addition	B-NP	NN	O	1	PMOD	O
O	O	1596	1597	,	,	O	,	O	5	P	O
O	O	1598	1609	antagonists	antagonist	B-NP	NNS	O	5	SUB	O
O	O	1610	1614	show	show	B-VP	VBP	O	0	ROOT	O
O	O	1615	1625	distinctly	distinctly	B-NP	RB	O	7	AMOD	O
O	O	1626	1635	different	different	I-NP	JJ	O	8	NMOD	O
O	O	1636	1648	requirements	requirement	I-NP	NNS	O	5	OBJ	O
O	O	1649	1652	for	for	B-PP	IN	O	8	NMOD	O
O	O	1653	1662	efficient	efficient	B-NP	JJ	O	11	NMOD	O
O	O	1663	1670	binding	binding	I-NP	NN	O	9	PMOD	O
O	O	1670	1671	,	,	O	,	O	8	P	O
O	O	1672	1677	which	which	B-NP	WDT	O	8	NMOD	O
O	O	1678	1681	may	may	B-VP	MD	O	13	SBAR	O
O	O	1682	1692	contribute	contribute	I-VP	VB	O	14	VC	O
O	O	1693	1695	to	to	B-PP	TO	O	15	VMOD	O
O	O	1696	1701	their	their	B-NP	PRP$	O	18	NMOD	O
O	O	1702	1714	interference	interference	I-NP	NN	O	16	PMOD	O
O	O	1715	1717	in	in	B-PP	IN	O	18	NMOD	O
O	O	1718	1721	the	the	B-NP	DT	O	25	NMOD	O
O	O	1722	1728	ligand	ligand	I-NP	NN	O	25	NMOD	O
O	O	1728	1729	-	-	B-NP	HYPH	O	25	NMOD	O
O	O	1729	1738	inducible	inducible	I-NP	JJ	O	25	NMOD	O
O	O	1739	1754	transactivation	transactivation	I-NP	NN	O	25	NMOD	O
O	O	1755	1763	function	function	I-NP	NN	O	19	PMOD	O
O	O	1764	1766	of	of	B-PP	IN	O	25	NMOD	O
T9	B-Protein	1767	1770	RAR	RAR	B-NP	NN	B-protein	28	NMOD	B-protein
T9	I-Protein	1771	1776	alpha	alpha	I-NP	NN	I-protein	26	PMOD	I-protein
O	O	1776	1777	.	.	O	.	O	5	P	O
